NasdaqGS - Nasdaq Real Time Price USD
Allakos Inc. (ALLK)
At close: November 6 at 4:00 PM EST
After hours: November 6 at 5:11 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
187,548.0000
196,056.0000
322,429.0000
271,475.0000
157,057.0000
Operating Income
-187,548.0000
-196,056.0000
-322,429.0000
-271,475.0000
-157,057.0000
Net Non Operating Interest Income Expense
8,926.0000
10,347.0000
3,673.0000
377.0000
4,313.0000
Other Income Expense
-27,377.0000
8.0000
-1,196.0000
1,238.0000
-736.0000
Pretax Income
-205,999.0000
-185,701.0000
-319,952.0000
-269,860.0000
-153,480.0000
Net Income Common Stockholders
-205,999.0000
-185,701.0000
-319,952.0000
-269,860.0000
-153,480.0000
Diluted NI Available to Com Stockholders
-205,999.0000
-185,701.0000
-319,952.0000
-269,860.0000
-153,480.0000
Basic EPS
-2.35
-2.14
-5.06
-5.01
-3.10
Diluted EPS
-2.35
-2.14
-5.06
-5.01
-3.10
Basic Average Shares
87,846.0000
86,798.0000
63,284.0000
53,832.0000
49,492.0000
Diluted Average Shares
87,846.0000
86,798.0000
63,284.0000
53,832.0000
49,492.0000
Total Operating Income as Reported
-214,895.0000
-196,056.0000
-322,429.0000
-271,475.0000
-157,057.0000
Total Expenses
187,548.0000
196,056.0000
322,429.0000
271,475.0000
157,057.0000
Net Income from Continuing & Discontinued Operation
-205,999.0000
-185,701.0000
-319,952.0000
-269,860.0000
-153,480.0000
Normalized Income
-178,652.0000
-185,701.0000
-319,952.0000
-269,860.0000
-153,480.0000
Interest Income
8,926.0000
10,347.0000
3,673.0000
377.0000
4,313.0000
Net Interest Income
8,926.0000
10,347.0000
3,673.0000
377.0000
4,313.0000
EBIT
-187,548.0000
-196,056.0000
-322,429.0000
-271,475.0000
-157,057.0000
EBITDA
-182,507.0000
-189,915.0000
-315,358.0000
-269,165.0000
-155,512.0000
Reconciled Depreciation
5,041.0000
6,141.0000
7,071.0000
2,310.0000
1,545.0000
Net Income from Continuing Operation Net Minority Interest
-205,999.0000
-185,701.0000
-319,952.0000
-269,860.0000
-153,480.0000
Total Unusual Items Excluding Goodwill
-27,347.0000
--
--
--
--
Total Unusual Items
-27,347.0000
--
--
--
--
Normalized EBITDA
-155,160.0000
-189,915.0000
-315,358.0000
-269,165.0000
-155,512.0000
12/31/2020 - 7/19/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
XLO Xilio Therapeutics, Inc.
1.2900
-1.53%
QNCX Quince Therapeutics, Inc.
1.4600
+4.29%
NUVB Nuvation Bio Inc.
2.5400
+9.48%
EPIX ESSA Pharma Inc.
1.7100
+0.59%
LYEL Lyell Immunopharma, Inc.
1.4800
+19.35%
ZNTL Zentalis Pharmaceuticals, Inc.
3.8400
+1.59%
SYRS Syros Pharmaceuticals, Inc.
2.4500
-3.16%
ANAB AnaptysBio, Inc.
22.21
+11.72%
VRPX Virpax Pharmaceuticals, Inc.
0.7125
+2.95%
ACLX Arcellx, Inc.
92.98
+6.73%